IGF1 and cancer: IGFBP‐6 is likely involved in the attraction of inflammatory and immune cells in this context.25 Previous studies have shown that in both normal and cancer cells, IGFBP‐6 impairs migration by inhibiting IGF‐II actions40, 41, 42 and by promoting EGR (early growth response protein)‐1 transcription in an IGF‐independent manner.51 On the other hand, IGFBP‐6 promotes rhabdomyosarcoma (RMS) cell migration by an IGF‐independent mechanism that involves MAPK pathway activation.69, 70 These results raised the possibility that a receptor or membrane protein may be involved.